Clinical trial registry record

To Evaluate the Efficacy and Safety of NMN as an Anti-ageing Supplement in Middle Aged and Older (40-65 Years) Adults

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase not reported study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated October 1, 2021.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT04823260
Last registry update
October 1, 2021
Status
Completed
Phase
Phase not reported
Sponsor
Abinopharm, Inc
Enrollment
90
Countries
India
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase not reported
Study design
RANDOMIZED · PARALLEL · OTHER · QUADRUPLE
Evidence population
Human clinical study registration
Participants
90
Population
ALL · 40 Years to 65 Years
Duration
2021-05-25 to 2021-09-09
Intervention
Nicotinamide Mononucleotide; Placebo
Comparator
Arm A = 300 mg NMN supplement (n = 20); Arm B = Placebo 300 mg (n=07); Arm C = NMN Supplement 600 mg (n= 20); Arm D = Placebo 600 mg (n=07); Arm E = NMN Supplement 900 mg (n=10); Arm F = Placebo 900 mg (n=06)
Outcomes measured
Blood cellular NAD+/ NADH — Baseline; Blood cellular NAD+/ NADH — 1 month; Blood cellular NAD+/ NADH — 2 month; Six walking endurance test — Baseline; Six walking endurance test — 1 month; Six walking endurance test — 2 month; SF-36 questionnaire — Baseline; SF-36 questionnaire — 1 month; SF-36 questionnaire — 2 month; PART II : Telomerase test results — Baseline; PART II : Telomerase test results — 2 Months; PART II : SF-36 questionnaire — Baseline; PART II : SF-36 questionnaire — 2 months; safety of NMN — Baseline; safety of NMN — 2 Months; Tolerability of NMN — Baseline; Tolerability of NMN — 2 months; Safety of the different NMN doses — 2 Months; Tolerability different NMN doses — Baseline; Tolerability different NMN doses — 2 Months
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase not reportedA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • NAD metabolism · 100%Title contains controlled term: nmn. Abstract contains controlled term: nmn. Source terminology contains: nicotinamide mononucleotide. Title supplies longevity context: ageing. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.

nad metabolism
Open primary sourceExport JSON